Spain: Sublicense Agreement Almirall and Bicosome Enter into a Collaboration

Editor: Alexander Stark

Almirall, a global pharmaceutical company, and Bicosome, a start-up company that develops and commercializes high performance cosmetic and dermopharmaceutical ingredients, announced that they have entered into a research, collaboration and sublicense agreement.

Related Vendors

Almirall and Bicosome enter into a collaboration and sublicense agreement for the development of topical drug delivery formulations.
Almirall and Bicosome enter into a collaboration and sublicense agreement for the development of topical drug delivery formulations.
(Picture: Almirall)

Barcelona/Spain – The agreement concerns the development of multiple topical dermatological products, based upon Bicosome's proprietary patented delivery technology platform, Bicosome Technology.

In accordance with the terms of the agreement, Bicosome will be responsible for the research activities to deliver preclinical product prototypes using their proprietary encapsulating system and Almirall will perform the clinical development, regulatory filings, manufacturing and commercialization activities of the developed products.

Furthermore, Bicosome grants Almirall a sublicense to develop and commercialize products in certain dermatological indications. Bicosome will receive research payments and is entitled to potential development milestone payments as well as tiered royalties on future Net Sales and sales milestones.

Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy.

Unfold for details of your consent

(ID:44068034)